

**Question for written answer E-001918/2025
to the Commission**
Rule 144
Valentina Palmisano (The Left)

Subject: EU strategy on price transparency and access to medicines

Major pharmaceutical companies have recently announced investments of over USD 165 billion in the United States, thus shifting part of their production apparatus.

The CEOs of Novartis and Sanofi have criticised EU policy, which they deem to be unattractive, citing regulatory uncertainty and price controls.

The Commission has submitted proposals such as a European price list based on US prices, the elimination of spending caps and a European target for innovative medicines.

Given the foregoing and the fact that equitable access to medicines and the sustainability of healthcare systems are fundamental rights, that World Health Organisation resolution WHA72.8 calls for price transparency but no such policy enforces it in Europe, and that the evaluation of medicines does not systematically include added therapeutic value, can the Commission say:

1. What stance it takes on Big Pharma's proposals and the associated risks for the sustainability of healthcare systems and equitable access to medicines?
2. What measures it intends to take to increase price transparency in line with Resolution WHA72.8 and improve information exchange between Member States?
3. Whether it intends to introduce the criterion of added therapeutic value in the assessment of medicines at European level, with a view to steering innovation towards real clinical benefits and avoiding incremental innovation?

Submitted: 14.5.2025